Logo image of SURG

SURGEPAYS INC (SURG) Stock Fundamental Analysis

NASDAQ:SURG - Nasdaq - US86882L2043 - Common Stock - Currency: USD

3.06  -0.1 (-3.16%)

After market: 3.05 -0.01 (-0.33%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SURG. SURG was compared to 21 industry peers in the Wireless Telecommunication Services industry. SURG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SURG has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURG has reported negative net income.
SURG had a negative operating cash flow in the past year.
SURG had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SURG reported negative operating cash flow in multiple years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of SURG (-190.73%) is worse than 95.24% of its industry peers.
The Return On Equity of SURG (-298.57%) is worse than 90.48% of its industry peers.
Industry RankSector Rank
ROA -190.73%
ROE -298.57%
ROIC N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SURG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SURG has more shares outstanding
Compared to 5 years ago, SURG has more shares outstanding
Compared to 1 year ago, SURG has a worse debt to assets ratio.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -1.71, we must say that SURG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.71, SURG is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.15 indicates that SURG is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.15, SURG belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -1.71
ROIC/WACCN/A
WACC9.11%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 2.95 indicates that SURG has no problem at all paying its short term obligations.
The Current ratio of SURG (2.95) is better than 100.00% of its industry peers.
SURG has a Quick Ratio of 2.66. This indicates that SURG is financially healthy and has no problem in meeting its short term obligations.
SURG has a better Quick ratio (2.66) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.66
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

SURG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -342.61%.
Looking at the last year, SURG shows a very negative growth in Revenue. The Revenue has decreased by -55.61% in the last year.
The Revenue has been growing by 18.83% on average over the past years. This is quite good.
EPS 1Y (TTM)-342.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-642.86%
Revenue 1Y (TTM)-55.61%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-66.35%

3.2 Future

SURG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.15% yearly.
SURG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.68% yearly.
EPS Next Y96.29%
EPS Next 2Y49.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year104.28%
Revenue Next 2Y75.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 1 -1 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SURG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 5.83, the valuation of SURG can be described as very cheap.
100.00% of the companies in the same industry are more expensive than SURG, based on the Price/Forward Earnings ratio.
SURG is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.83
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SURG's earnings are expected to grow with 49.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.15%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SURG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (5/23/2025, 8:57:40 PM)

After market: 3.05 -0.01 (-0.33%)

3.06

-0.1 (-3.16%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners10.05%
Inst Owner Change-2.26%
Ins Owners31.04%
Ins Owner Change-0.77%
Market Cap62.45M
Analysts80
Price Target7.01 (129.08%)
Short Float %3.67%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-236.21%
Min EPS beat(2)-304.04%
Max EPS beat(2)-168.38%
EPS beat(4)0
Avg EPS beat(4)-337.76%
Min EPS beat(4)-824.37%
Max EPS beat(4)-54.25%
EPS beat(8)3
Avg EPS beat(8)-8.82%
EPS beat(12)4
Avg EPS beat(12)-69.12%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-15.73%
Min Revenue beat(2)-45.89%
Max Revenue beat(2)14.43%
Revenue beat(4)2
Avg Revenue beat(4)-6.63%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)14.43%
Revenue beat(8)2
Avg Revenue beat(8)-7.49%
Revenue beat(12)4
Avg Revenue beat(12)-6.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.85%
PT rev (3m)19.57%
EPS NQ rev (1m)-32.86%
EPS NQ rev (3m)-69.09%
EPS NY rev (1m)-30.77%
EPS NY rev (3m)47.69%
Revenue NQ rev (1m)-2.79%
Revenue NQ rev (3m)-7.57%
Revenue NY rev (1m)27.64%
Revenue NY rev (3m)27.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.83
P/S 1.03
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 5.92
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)0.53
Fwd EY17.17%
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS2.98
BVpS0.75
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -190.73%
ROE -298.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.54
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.1%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.66
Altman-Z -1.71
F-Score2
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-642.86%
EPS Next Y96.29%
EPS Next 2Y49.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-55.61%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-66.35%
Revenue Next Year104.28%
Revenue Next 2Y75.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-321.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year113.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-312.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-307.15%
OCF growth 3YN/A
OCF growth 5YN/A